Avexitide acetate is under clinical development by Eiger BioPharmaceuticals and currently in Phase II for Hypoglycemia. According to GlobalData, Phase II drugs for Hypoglycemia have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Avexitide acetate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Avexitide acetate overview
Avexitide acetate is under development for the treatment of bariatric surgery-induced hyperinsulinemic hypoglycemia and non-insulinoma pancreatogenous hypoglycemia syndrome. It is developed as a new liquid formulation and is administered through intravenous and subcutaneous routes. The therapeutic candidate is a 31 amino acid peptide fragment of exenatide. It is a new chemical entity (NCE). It targets glucagon-like peptide 1 receptor.
Eiger BioPharmaceuticals overview
Eiger BioPharmaceuticals (Eiger), formerly known as Celladon, is a biopharmaceutical company that focuses on the clinical-stage development and commercialization of novel drugs for the treatment of orphan diseases. The company provides products such as lonafarnib and lambda which are used for the treatment of hepatitis delta virus infection; exendin 9-39 post-bariatric hypoglycemia; ubenimex for lymphedema and pulmonary arterial hypertension. It also offers late-stage portfolio products candidates that potential to address diseases for which unmet medical services. Eiger provides clinical development and commercialization of broad range of therapeutics. The company also offers post-bariatric hypoglycemia prevention services. Eiger is headquartered in Palo Alto, California, the US.
For a complete picture of Avexitide acetate’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
